STORM Therapeutics | pharmaphorum

Skip to main content

Wednesday 2 September 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

STORM Therapeutics

News

Saqib Islam

Beeline raises $300m for BMS drugs, and other biofinancings

Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.

Partner Content

RNA

Partner Content

STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics

STORM Therapeutics Exclusive Speaker Interview

Partner Content

RNA

Partner Content

STORM Therapeutics Announces Publication in Nature on RNA Ep...

RNA Therapeutics

Editor's Picks

Revolution's ASCO showstopper gets FDA greenlight

Anthropic AI tool conducts physical scientific experiments

UK MHRA authorises orforglipron private prescription

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321

Sword Health buys Headspace in $200m to $300m deal

News

PMV cues up filing for first p53-directed cancer therapy

PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company